Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.27). On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 7.5%

NASDAQ RLMD opened at $0.57 on Wednesday. The company’s 50 day moving average is $0.66 and its 200-day moving average is $0.46. Relmada Therapeutics has a 12-month low of $0.24 and a 12-month high of $3.98. The firm has a market cap of $18.89 million, a P/E ratio of -0.23 and a beta of 0.66.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Relmada Therapeutics to a “strong sell” rating in a research report on Saturday, May 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Relmada Therapeutics currently has an average rating of “Hold” and an average target price of $5.00.

Insider Activity

In other news, COO Paul Edward Kelly acquired 200,000 shares of Relmada Therapeutics stock in a transaction that occurred on Friday, May 16th. The stock was bought at an average price of $0.43 per share, with a total value of $86,000.00. Following the completion of the purchase, the chief operating officer owned 412,295 shares in the company, valued at approximately $177,286.85. The trade was a 94.21% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Maged Shenouda acquired 60,000 shares of Relmada Therapeutics stock in a transaction that occurred on Tuesday, May 20th. The shares were purchased at an average cost of $0.52 per share, with a total value of $31,200.00. Following the purchase, the chief financial officer owned 288,335 shares of the company’s stock, valued at $149,934.20. This represents a 26.28% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 628,961 shares of company stock valued at $286,332 over the last quarter. Company insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Relmada Therapeutics

A hedge fund recently bought a new stake in Relmada Therapeutics stock. Goldman Sachs Group Inc. acquired a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 120,852 shares of the company’s stock, valued at approximately $33,000. Goldman Sachs Group Inc. owned approximately 0.36% of Relmada Therapeutics at the end of the most recent quarter. Institutional investors own 45.24% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.